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Abstract
Background: Apoptosis-stimulating of p53 protein 2 (ASPP2) is one of the ASPP family members and it has been
reported to be associated with human cancer. However, the role of it in pancreatic cancer is still not clear.
Methods: We analyzed the expression level of ASPP2 in cancer tissue samples with RT-qPCR, Western Blotting assay
and immunohistochemistry staining. We studied the biological function of ASPP2 and its mechanism with gene
overexpression and gene silencing technologies. We determined the sensitivity of pancreatic cells with differential
ASPP2 level to gemcitabine and whether autophagy inhibition affected the gemcitabine resistance, both in vitro
and in vivo.
Results: Expression of ASPP2 was downregulated in cancerous tissues in comparison with para-cancerous tissues.
ASPP2 expression was linked to clinical outcomes in patients and down-regulation of ASPP2 increased cell
proliferation, autophagic flux, the activity of AMP Kinase of pancreatic cancer cells and vice versa. Knockdown of
ASPP2 results in increased resistance to gemcitabine, which was attributed to the enhanced autophagy.
Conclusions: ASSP2 expression is lower in cancerous tissues and decreased ASPP2 lead to higher cancer cells
proliferation and autophagic flux, which contribute to the gemcitabine resistance.
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Background
Pancreatic cancer (PC) is the fourth leading cause of
cancer-related deaths in the world with 5-year survival
rate of 4 %.[1, 2] Currently, the main therapeutic options
include surgical resection, radiation therapy, chemother-
apy and immunotherapy.[3] However, in most cases after
surgery treatment, the tumor recurs within 1–2 years
and patients develop metastasis. [4] In case of patients
with inoperable PC, the standard treatment is chemo-
therapy. In this group, the survival of the patients is just
increased by a dismal 5 weeks.[3, 4] The poor outcome
of chemotherapy is partly due to the drug-resistant
phenotype of PC cells.[5–9] however, the mechanism is
not fully elucidated. Thus, failure of effective chemother-
apy results in high mortality in PC patients, which the
importance of understanding the mechanism of drug re-
sistance and developing strategies that would improve
the outcome of chemotherapy.
ASPP2 is a pro-apoptotic regulator that belongs to
ASPP family.[10] The expression of ASPP2 is frequently
suppressed in many cancers in relation to enhanced
apoptosis through the binding to p53 for transcriptional
transactivation.[11–15] Surprisingly, a number of ASPP2
binding partners that are involved in biological pathways
other than apoptosis have also been identified,[10] sug-
gesting that ASPP2 function is far more complex than
simply enhancing p53-mediated apoptosis.
Autophagy acts as a survival mechanism under con-
ditions of stress, maintaining cellular integrity by re-
generating metabolic precursors and clearing subcellular
debris [16]. Autophagy is wildly involved in the tumorous
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development and drug resistance.[17–20] A recent study
has found that ASPP2 inhibits RAS-induced autoph-
agy by preventing ATG16/ATG5/ATG12 formation
and induces autophagic apoptosis by releasing Beclin-
1 from cytoplasmic Bcl-2-Beclin-1 complexes in hepa-
toma cells.[21, 22] However, the function and detailed
mechanism of ASPP2 which regulate autophagy is still
not clear, especially in pancreatic cancer. In this study, we
investigated the role and mechanism of ASPP2 for pancre-
atic cancer drug resistance.
Our data suggest that ASPP2 express lower in pan-
creatic cancer cells in comparison with para-cancer
cells and decrease of ASPP2 expression is also linked to
poor clinical outcomes in patients. Additionally, the de-
creased expression of ASPP2 can lead to enhanced au-
tophagy through AMP kinase pathway in pancreatic
cancer and resistance to gemcitabine in vitro and in
vivo. Furthermore, the anticancer activity of ASPP2 in
pancreatic cancer is partially due to its regulation on
autophagy. Our study highlights ASPP2 and autophagy
can be targeted for improvement of the efficiency of
gemcitabine treatment and development of novel anti-
pancreatic cancer drugs.
Results
ASSP2 expression is lower in cancerous tissues and
predicts a poor prognosis
ASPP2 plays a key role in apoptosis regulation in the
intrinsic and extrinsic apoptotic pathways [23, 24]
and widely expressed in many human tissues.[25] The
expression of ASPP2 can be enhanced in response to
DNA damage,[13] and was down-regulated in both
metastatic and invasive cells as compared to normal
breast epithelium.[26] To exam the levels of expres-
sion of ASSP2 in the pancreatic cancer tissues and
para-cancerous tissues, we determined ASSP2 ex-
pression level with RT-qPCR assay or immunoblot-
ting assay, the ASSP2 expression level was less
abundant in pancreatic cancer tissues compared with
para-cancerous tissues (Fig. 1a and b). We also ana-
lyzed the patients’ samples with IHC assay (Table 1).
As presented in Fig. 1c (left panel, 1# and 11# sam-
ples as the representative samples), the results sug-
gest that ASSP2 protein expression was much lower
in cancerous tissues (Fig. 1c, right panel). Further-
more, the ASPP2 low expression patients were found
to exhibit high Histopathological grade (Table 1).
More importantly, significant differences in both
overall survival and disease-free survival were found
among ASPP2 low/high groups (Fig. 1d). Taken to-
gether, all the data suggest that ASSP2 expression is
lower in cancerous tissues than papa-cancerous tis-
sues and it could be an independent prognostic pre-
dictor for pancreatic cancer.
ASPP2 inhibit proliferation of pancreatic cancer cell
To study the role of ASSP2 in cancer, we firstly ana-
lyzed its expression in series of pancreatic cancer cell
lines using NCBI GEO database [27] and the data
suggest that ASSP2 expression significantly differs in
different PC cell lines. Low ASPP2 expression cell line
BxPC-3 and high ASPP2 expression cell line SW1990
were used for further research (Fig. 2a). We organized
ASPP2 stably over-expression cell lines in BxPC-3 and
ASPP2 stably knockdown cell lines in SW1990, the
mRNA and protein expression of ASPP2 were shown
(Fig. 2b, c and Additional file 1: Figure S1A). The #2 of
ASPP2 knockdown cell lines was used for next experi-
ments. Forced ASPP2 over-expression resulted in a signifi-
cant decrease of cancer cell proliferation, Knockdown of
ASPP2 enhanced proliferative activity (Fig. 2d). Consist-
ently, over-expression of ASPP2 attenuated cancer cell
clone formation and vice versa (Fig. 2e). Together, these
results reveal that down-regulation of ASPP2 could
enhance cell proliferation of pancreatic cancer.
ASPP2 negatively regulate basal autophagy in pancreatic
cancer cell lines
Recently, two groups found that ASPP2 could regulate sur-
vival autophagy and autophagic apoptosis through different
ways in hepatoma cells,[21, 22] which indicated that ASPP2
could be the Indispensable regulator in autophagy. In pan-
creatic cancer, autophagy play essential function in cell
growth under basal condition.[28] To examine its regula-
tion on basal autophagy, firstly, we analyzed the autophagic
activities of pancreatic cancer cell lines. Unexpectedly,
BxPC-3 cells with low ASPP2 expression expressed higher
LC3-II, the marker of autophagosomes,[29] sw1990 cells
with high ASPP2 expression formatted less LC3-II (Fig. 3a).
For directly observing the autopahgy process, we also trans-
fected GFP-LC3 into these four PC cell lines and analyze
the formation of autophagosomes,[29] we found that more
autophagosomes were formed in the BxPC-3 cells than
SW1990, PANC1and MiAPaca-2 cells (Fig. 3b). All the data
presented suggest that autophagy negatively correlated with
the expression of ASPP2.
Based on these data, we hypothesized that ASSP2 can
negatively regulate basal autophagy in pancreatic cancer
cells. To test this hypothesis, we checked the
Autophagy-Related Gene Family in BxPC-3 cells with
ASPP2 overexpression and in SW1990 cells with ASPP2
knockdown. Overexpression of ASPP2 could signifi-
cantly decrease the amount of LC3-II and ATG family
expression, and knockdown of ASPP2 enhanced it
(Fig. 3c). With GFP-LC3 system, we confirmed the
regulation of ASPP2 in autophagy (Fig. 3d). In addition,
as presented in Fig. 3e, the accumulation of autophagic
vacuoles was dramatically decreased in ASPP2 overex-
pression BxPC3 cells and silencing of ASPP2 reversed
Song et al. Molecular Cancer  (2015) 14:177 Page 2 of 12
it. Furthermore, for detecting the autophagic flux, we
examined mRFP-GFP-LC3 puncta formation with fluor-
escence microscope. Consistently, ASPP2 decreased the
autophagosomal-lysosomal fusion process, which also
supports ASPP2 as the negative regulator for autophagy
under basal condition (Fig. 3f ). As a P53 interacting-
protein,ASPP2 often regulate cell function in P53-
dependent way. P53 was also reported as the core-
regulator in autophagy.[30] to exclude the function of
P53 in the regulation of autophagy, we also check the
basal autophagy with P53 inhibitor, pifithrin-α [31]. How-
ever, inhibition of P53 could not reverse the function of
ASPP2 in autophagy, which suggested that ASPP2 regu-
lated basal autophagy in P53-indepdent way (Additional
file 1: Figure S1B).
ASPP2 regulate autophagy through AMPK-mTOR
pathways
AMPK is a key cellular energy sensor and functions
to maintain energy homeostasis upon nutrient starva-
tion,[32] it could regulate autophagy through mTOR
pathway.[33] Firstly, we checked the phosphorylation
of AMPK and TSC2. Down-regulation of ASPP2 could in-
crease the phosphorylation of AMPK and TSC2 and vice
versa (Fig. 4a). For confirming the ASPP2 regulate autoph-
agy through AMPK, we knockdown the AMPK expression
with shRNA (Fig. 4b),and found that AMPK knockdown
could significantly inhibit the autophagic flux upregulation
induced by ASPP2 knockdown (Fig. 4c,d,e). These results
indicate that ASPP2 regulate autophagy through AMPK-
mTOR pathways.
Fig. 1 Downregulation of ASPP2 in Pancreatic cancer tissues. a mRNA from pancreatic cancer tissues and para-cancerous tissues was extracted and
RT–qPCR analysis was performed to determine the expression of ASPP2; b Pancreatic cancer tissues and para-cancerous tissues from 12 patients were
collected and Western Blot assay was performed to analyze the ASPP2 expression; c 65 Pancreatic cancer tissues and para-cancerous tissues were
analyzed by immunohistochemical method to determine ASPP2 expression level. Representative samples were shown. The bar graph shows the
statistical analysis of ASPP2 in pancreatic cancer tissues and para-cancerous tissues. d The disease-free and overall survival rates of patients of c were
compared between the low-ASPP2 and high-ASPP2 groups. Data represent the mean ± SD of three independent experiments (*P < 0.05, **P < 0.01)
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ASPP2 can facilitate gemcitabine induced cell apoptosis
through regulation of autophagy in vitro and in vivo
Gemcitabine is currently the standard chemotherapy
treatment at all stages of pancreatic cancer.[34] Survival
benefit and clinical impact however remain moderate
due to a high degree of drug resistance. To dissect the
effect of ASPP2 on gemcitabine mediated cell apoptosis,
we treated these cells with gemcitabine. As shown in
Fig. 5a, overexpression of ASPP2 can promote the gem-
citabine induced cell death and knockdown of ASPP2
could inhibit it. To further define the role of ASPP2 in
determining the sensitivity of PC to gemcitabine, we
checked the cell apoptosis induced by gemcitabine, which
is consistently with the cell death results (Fig. 5b). Apop-
tosis protein expression also proved it (Fig. 5c). All the re-
sults suggest that ASPP2 expression level can determine
the susceptibility of the cells to gemcitabine treatment.
As ASPP2 could interact with P53 to Specifically Stimu-
late the Apoptotic Function of p53, we firstly checked that
whether ASPP2 regulated gemcitabine-resistance in pan-
creatic cancer. With pifithrin-α treatment, we found that
inhibition of P53 could not reverse the ASPP2-inudced
cell apoptosis, which suggested that ASPP2 regulated
gemcitabine-induced cell death in P53-indepdent way
(Fig. 5d,e). As shown previously, ASPP2 can negatively
regulate autophagic activity, so we next exam whether
ASPP2 determining the susceptibility of cells to gemcita-
bine is dependent on its regulation of autophagy. To an-
swer this question, we treated ASPP2 shRNA transduced
SW1990 cells with gemcitabine in the presence or absence
of CQ and 3-MA, which are the widely used autophagy
inhibitors, and cell death and cell apoptosis were analyzed.
The protection of knockdown of ASPP2 in SW1990 cells
from gemcitabine induced apoptosis was dramatically im-
paired in the presence of autophagy inhibitors, suggesting
that ASPP2 regulate gemcitabine induced cell apoptosis
via autophagy (Fig. 6a, b, c). To dissect the ASPP2 role in
regulation of gemcitabine induced cell apoptosis in vivo,
we inoculated SW1990 cells with ASPP2 knockdown into
nude mice and determine the tumor size at indicated time
point post-inoculation. As shown in Fig. 6d and e, ASPP2
knockdown cells were more resistant to gemcitabine treat-
ment; however, this is significantly impaired following
treatment of CQ, further establishing the essential role of
autophagy in determining the resistance to gemcitabine in
vivo. Collectively, all the data presented here demonstrate
that decrease expression of ASPP2 can confer cell the in-
sensitivity to gemcitabine, which is dependent on its acti-
vation of autophagy.
Discussion
The capability of cancer cells to escape the cytotoxic
effect of chemotherapeutic drug may result from genetic
mutations that affect cell cycle, apoptosis or accumula-
tion of drugs inside of the cell.[35, 36] In this study, we
revealed the mechanisms by which pancreatic cancer
cells to escape chemotherapeutic drug (gemcitabine)
mediated cell apoptosis via decrease of ASPP2 expres-
sion to activate the autophagic activity.
We found that ASPP2 expression level was preferen-
tially down-regulated in cancerous tissues compared
with para-cancerous tissues from the pancreatic cancer
patients. ASPP2 expression levels were different in dis-
tinct PC cell lines and ASPP2 could negatively regulated
cancer cell proliferation. We found that the expression
levels of ASPP2 negatively associated with the autopha-
gic activities in the pancreatic cancer cell lines. Through
overexpression and knockdown of ASPP2, we demon-
strated that ASPP2 can negatively regulate autophagic
activity. Furthermore, we demonstrated that ASPP2 reg-
ulated autophagy through AMPK-mTOR pathways. We
also found that ASPP2 could promote the gemcitabine
induced cell apoptosis in pancreatic cancer cells, and
knockdown ASPP2 can enable the phenotype of the cells
to resistant for gemcitabine treatment. In addition, the
effect of protecting cells from gemcitabine treatment
through knockdown of ASPP2 was significantly compro-
mised by repression of autophagy in vitro and in vivo,
indicating that ASPP2 determining the sensitivity of
Table 1 Correlation between ASPP2 expression levels and










65 54.8+13.2 59.1+11.2 0.362
Gender
Male 44 35 9 0.061
Female 21 12 9
Histopathological grade
G1 18 17 1 0.013
G2,3 47 30 17
Depth of invasion
T1, 2 41 27 14 0.133
T3, 4 24 20 4
Lymph node metastasis
Negative 33 23 10 0.639
Positive 32 24 8
Pathologic stage
I, II 59 44 15 0.203
III, IV 6 3 3
Abbreviations: PC pancreatic cancer
Patients with PC were divided into ASPP2 “High” group (whose density was
higher than the median) and “Low” group (whose density was lower than the
median). The patient and disease profiles in each group were compared
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pancreatic cancer cells to gemcitabine was dependent on
its regulation of autophagy (Fig. 6f ).
Autophagy is the ubiquitous cellular process that involves
cell degradation of unnecessary or dysfunctional cellular
components through the lysosomal machinery; it plays a
critical role in removing protein aggregates, as well as
damaged or excess organelles, to maintain intracellular
homeostasis [37]. Autophagy is widely involved in many
physiological process, such as cell survival, embryo develop-
ment, longevity, clearance of toxic aggregate-prone proteins,
cell surface receptor trafficking and protection of host from
pathogen infection.[19, 38–40] Dysregulation of autophagy
contributes to a number of diseases including tumorigen-
esis.[17, 19] However, the role of autophagy in cancer is still
controversial. It was reported that inhibition of autophagy
can increase chemotherapy-induced apoptosis in hepatocar-
cinoma cells,[41] colon cancer,[42] and esophageal cancer
cells.[43] In our study, we found that the decrease of ASPP2
could enhance the autophagic activity of pancreatic cancer
cells, and this lead to pancreatic cancer cells less sensitive to
gemcitabine induced cell apoptosis in vitro and in vivo;
Lower expression of ASPP2 was also correlated with poor
outcome of gemcitabine treatment and survival rates. We
also found that ASPP2 was down-regulated in the pancre-
atic cancer tissues compared with para-pancreatic cancer
tissues, suggesting that decrease of ASPP2 leading to up-
regulated autophagy might serve as a chemotherapy in-
trinsic defense mechanism for pancreatic cancer cells.
Fig. 2 ASPP2 inhibits proliferation of pancreatic cancer cell. a The expression of ASPP2 in different pancreatic cancer cell lines were
shown. b The mRNA and protein expression of exogenous ASPP2 in BxPC-3 cells with stable ASPP2. c The mRNA and protein expression
of ASPP2 in SW1990 cells which were stably knockdown ASPP2. d CCK-8 assays were performed in BxPC-3 cells with stable ASPP2 and
SW1990 cells with ASPP2 stably knockdown in the indicated time. e Colony formation assays were performed in the cells of (D). Data
represent the mean ± SD of three independent experiments (*P < 0.05, **P < 0.01)
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Fig. 3 ASPP2 negatively regulate basal autophagy in pancreatic cancer cell lines. a Immunoblotting analysis was performed to determine LC3-II
in different pancreatic cancer cell lines; b GFP-LC3 was transfected into PC cells with different expression levels of ASPP2 and autophagosome
formations was observed under microscopy. Representative picture and the percentage of autophagic cells were calculated in 5 random fields.
c Western blot assay was performed to determine the expression of autophagy-related protein in BxPC-3 cells with stable ASPP2 and SW1990
cells with ASPP2 stably knockdown. d The cells in (C) were transfected with GFP-LC3 expression plasmids and autophagosome formations was
observed under microscopy. e Representative electron micrographs of autophagic vesicles were shown. Arrows denote autophagosomes. Magnified
images also were shown. f Representative images of LC3 staining in sh-con/sh-ASPP2 SW1990 cells infected with adenovirus-delivering mRFP-GFP-LC3.
Quantification of autophagosome and autolysosome formation represents punctures staining sites per cell of 5 independent images. Data represent
the mean ± SD of three independent experiments (*P < 0.05, **P < 0.01)
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Conclusions
Taken together, the data provide new insights into the
mechanisms by which decrease of ASPP2 in pancreatic
cancer cells can interfere with the effectiveness of
chemotherapy via enhanced autophagy. These results re-
veal ASPP2 as a crucial and unexpected switch for the
sensitivity to gemcitabine phenotype of pancreatic can-
cer via regulation of autophagy, which suggests that in
ASPP2 low expression patients gemcitabine combined
autophagy inhibitors could significantly promote cancer
cell apoptosis. Our data identify a molecular link be-
tween aberrant ASPP2 expression in pancreatic cancer
and susceptibility to gemcitabine treatment. A better un-
derstanding of this process may lead us to new methods
to overcome drug resistance in this aggressive disease.
Methods
Patients and samples
Twelve cancer tissues were (for qRT-PCR and WB) from
the patients which receiving curative resection in Changhai
Hospital, Shanghai, China from January 2013 to January
2014. 65 pancreatic cancer tissues (for IHC) were randomly
retrieved from pancreatic cancer patients receiving curative
resection in Changhai Hospital, Shanghai, China from Janu-
ary 2008 to January 2010 (see detailed clinical pathologic
features in Table 1). All patients were followed up until
January 2013, with a median observation time of 21 months.
Matched pairs of primary pancreatic cancer samples and
adjacent pancreatic tissues were used for analysis of ASPP2
expression. Participants provide their written informed con-
sent to participate in this study, and this study was per-
formed in according to an established protocol approved by
the Ethic Committee of Changhai Hospital.
Cell culture and reagent
Human pancreatic cancer cell lines BxPc-3, SW1990,
Panc-1 and MiaPaCa-2 were purchased from Cell Bank of
Type Culture Collection of Chinese Academy of Sciences.
They were cultured in 10 % FBS DMEM/RPMI1640 at
37 °C and 5 % CO2. Autophagy inhibitors, 3-MA and
Fig. 4 ASPP2 regulates autophagy through AMPK-mTOR pathways.
a Indicated proteins were detected with immunoblots in BxPC-3 cells
with stable ASPP2 and SW1990 cells with ASPP2 stably knockdown. b
Identification of shRNA activity of AMPK with RT-PCR and immunoblots.
c sh-con/sh-ASPP2 SW1990 cells with GFP-LC3 were transfected with
sh-Con/sh-AMPK, autophagosomes formation was observed under
microscopy. The percentage of autophagic cells was calculated in 5
random fields. d Indicated molecules were detected with immunoblots
in sh-con/sh-ASPP2 SW1990 cells transfected with sh-Con/sh-AMPK. e
sh-con/sh-ASPP2 SW1990 cells were transfected with sh-Con/sh-AMPK,
then infected with adenovirus-delivering mRFP-GFP-LC3. Quantification
of autophagosome and autolysosome formation represents punctures
staining sites per cell of 5 independent images. Data represent the
mean ± SD of three independent experiments (*P < 0.05, **P < 0.01)
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Fig. 5 ASPP2 can enhance gemcitabine induced cell apoptosis. a The surviving rate of cancer cells were detected with CCK-8 assays in BxPC-3 cells
with stable ASPP2 and SW1990 cells with ASPP2 stably knockdown treated with gemcitabine (1 μM) for indicated times.b the rate of apoptosis cells
were determine by Annexin V-FITC Apoptosis Detection Kit in cells of (A). c The indicated proteins were detected with immunoblots in BxPC-3 cells
with stable ASPP2 and SW1990 cells with ASPP2 stably knockdown treated with gemcitabine (1 μM) for 48 h. d,e the indicated molecules,
The surviving rate of cancer cells and the rate of apoptosis cells were detected in BxPC-3 cells with stable ASPP2 treated with gemcitabine (1 μM) or
gemcitabine (1 μM) plus pifithrin-α (10 μM). Data represent the mean ± SD of three independent experiments (*P < 0.05, **P < 0.01)
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Fig. 6 ASPP2 facilitate gemcitabine induced cell apoptosis through regulation of autophagy in vitro and vivo. a–b SW1990 cells with ASPP2 stably knockdown
treated with gemcitabine (1 μM) combined with/without CQ (10 μM)/3-MA (10 mM) for indicated times. The rate of surviving and apoptosis cells was detected.
c The indicated proteins were detected with immunoblots in SW1990 cells with ASPP2 stably knockdown treated with gemcitabine (1 μM) with or without
3-MA (10 mM) for 48 h. d SW1990 cells with ASPP2 stably knockdown were injected into nude mice; gemcitabine combined with CQ or not were injected
peritumorally. Tumors volumes were determined as the indicated time point. The expression of autophagy marker LC3 and ASPP2 were also shown in (e). f A
model for regulation of autophagy by ASPP2 in pancreatic cancer. Down-regulation of ASPP2 in pancreatic cancer promotes autophagy through activates
AMPK-mTOR pathways, resist to gemcitabine induced apoptosis. Data represent the mean± SD of three independent experiments (*P< 0.05, **P<0.01)
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chloroquine were purchased from Sigma (San Diego, CA).
ASPP2 antibody (sc-53861) is mouse monoclonal IgG1
against amino acids 691–1128 of ASPP2 of human origin.
The following antibodies were used for Western blot:
AMPK, p-AMPK, Actin (Santa Cruz), p-TSC2, TSC2,
Atg5, Atg7, Beclin1, p62, LC3 (Cell signal technology).
RT-qPCR assay
Total RNA was extracted by using Trizol reagent
(Invitrogen, Carlsbad, CA), and the reverse-transcrip-
tion reactions were performed using an M-MLV Reverse
Transcriptase kit (Invitrogen). Real-time PCR was per-
formed using a standard SYBR Green PCR kit (Toyobo,
Osaka, Japan). The primers used in RT-PCR as Followed.
mRNA levels are calculated as fold change of control.
Sequence of primers for real-time PCR
ShRNA Interference
We generated plasmid vectors encoding shRNAs tar-
geting ASPP2/AMPK or scramble shRNA using
pENTR™/U6 expression vector (Invitrogen, Carlsbad,
CA), and designated them as sh-Con and sh-ASPP2/
sh-AMPK, respectively. The synthesized oligonucleo-
tides were as follows:
MTT assay
The cancer cells were seeded in 100 μl growth medium
including 5 × 103 cells per well in 96-well plates. Cells
were treated with indicated regents or not. Every 24 h
until 72 h, CCK-8 solution was added to wells and incu-
bation at 37 °C for 2 h. Cell viability was measured. Via-
bility is given as a percent of the control value.
Colony formation assay
Five hundred cancer cells per well were seeds in 6-wells
plate. After cultured for 2–3 weeks, we terminate cell cul-
ture and wash the plate with PBS for two times, fixed cells
with 4 % Paraformaldehyde for 15 min, Incubate cells with
trypan blue for 10 min and wash the staining solution.
Apoptosis study
The Annexin V-FITC Apoptosis Detection Kit was pur-
chased from eBioscience, Inc. (San Diego, CA) and used
as recommended by manufacturer’s instruction.
Western blotting
Western blot analysis was carried out on 10 % SDS–
PAGE. Briefly, proteins were electrotransferred onto
nitrocellulose filter. After blocking for 1 h in PBS
with 0.1 % Tween 20 (PBST) and 5 % BSA, the
membranes were incubated over night with specified
primary antibody in PBST containing 5 % BSA. De-
tection was carried out by the use of HRP conju-
gated IgG assay kit (Sigma, St. Louis, MO). The
former band was stripped with Stripping buffer
(P0025, Beyotime) and incubated with other anti-
bodies. the relative density of WB bands with
ImageJ2X.
Transmission electron microscopy
Cells were fixed for 1 h at 4 °C in 1.6 % glutaraldehyde
in 0.1 M Sörensen phosphate buffer (pH 7.3), washed,
fixed again in aqueous 2 % osmium tetroxide and finally
embedded in Epon. Electron microscopy was performed
with a JEM-2000 EX transmission electron microscope,
on ultrathin sections (45 nm) stained with lead citrate
and uranyl acetate.
Immunohistochemistry (IHC)
Immunohistochemistry was performed using EnVi-
siontm system in according to the manufacture’s instruc-
tion. The antibody against ASPP2 (Santa Cruz) was
tested on sections from formalin-fixed paraffin-embedded
pancreatic cancer and para-cancerous tissue samples.
Images were obtained with a Zeiss AXIO Imager. A1
microscope (Zeiss, Jena, Germany) equipped with an
AxioCam (Zeiss) and the AxioVision 4.6 software
(Zeiss). The density of ASPP2 positive staining was
Primer Sequence (5′ to 3’)
ASPP2 forward primer 5’-TAAGCAATGGGAAACTTGTGG-3’
ASPP2 reverse primer 5’-CATCCGAGGCATAGTAGACGA-3’
18 s forward primer 5’-CGGCTACCACATCCAAGGAA-3’
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measured by a computerized image system (Leica
Microsystems Imaging Solutions Ltd, Cambridge,
United Kingdom). The patients were divided to two
groups (“low ASPP” and “high ASPP”) according to
median of ASPP2 expression in cancer samples.
Tumor xenograft study
All animal experimentation proceeds according to the
Standard of IACUC (Institutional Animal Care and Use
Committee) and performs in according to an established
protocol approved by the Ethic Committee of Changhai
Hospital. 2 × 106 cells Cancer cells were introduced by
subcutaneous implantation of in 10 % FBS DMEM into
6-week-old immunodeficient nude mice. 1 week later,
Gemcitabine (40 mg/kg) with or without Chloroquine
(CQ, 45 mg/kg) was injected every 2 days into tumors.
The mice were sacrificed 5 weeks after tumor implant-
ation. The volumes of tumors were measured and calcu-
lated as V = a x b2 x π/6.
Additional file
Additional file 1: Figure S1. (A) The expression of ASPP2 was detected
in BxPC-3 cells with stable ASSP2 over-expression and SW1990 cells
with ASPP2 knockdown. (B) Indicated molecules were measured with
immunoblots in BxPC-3 cells with stable ASSP2 over-expression
treated with pifithrin-α (10 μM). (JPEG 139 kb)
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